CY1114663T1 - 5-ανιλινοϊμιδαζοπυριδινες και μεθοδοι χρησης - Google Patents
5-ανιλινοϊμιδαζοπυριδινες και μεθοδοι χρησηςInfo
- Publication number
- CY1114663T1 CY1114663T1 CY20131101033T CY131101033T CY1114663T1 CY 1114663 T1 CY1114663 T1 CY 1114663T1 CY 20131101033 T CY20131101033 T CY 20131101033T CY 131101033 T CY131101033 T CY 131101033T CY 1114663 T1 CY1114663 T1 CY 1114663T1
- Authority
- CY
- Cyprus
- Prior art keywords
- methods
- imidazopyridines
- relates
- treating
- anilinoimidazopyrides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
Η εφεύρεση σχετίζεται με ιμιδαζοπυριδίνες του τύπου Ι με αντικαρκινική και/ή αντιφλεγμονώδη δραστικότητα και ειδικότερα με ιμιδαζοπυριδίνες που αναστέλλουν την δραστικότητα κινάσης ΜΕΚ. Η εφεύρεση παρέχει συνθέσεις και μεθόδους που είναι χρήσιμες για αναστολή ανώμαλης κυτταρικής αύξησης ή για θεραπευτική αγωγή υπερπλαστικής διαταραχής, ή για θεραπευτική αγωγή φλεγμονώδους ασθένειας σε θηλαστικό. Η εφεύρεση σχετίζεται επίσης με μεθόδους χρήσης των ενώσεων για in vitro, in situ, και in vivo διάγνωση ή θεραπευτική αγωγή κυττάρων θηλαστικού, ή σχετιζόμενων παθολογικών καταστάσεων.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1512907P | 2007-12-19 | 2007-12-19 | |
| US5401408P | 2008-05-16 | 2008-05-16 | |
| EP08869100.1A EP2222675B1 (en) | 2007-12-19 | 2008-12-18 | 5-anilinoimidazopyridines and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1114663T1 true CY1114663T1 (el) | 2016-10-05 |
Family
ID=40350172
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20131101033T CY1114663T1 (el) | 2007-12-19 | 2013-11-21 | 5-ανιλινοϊμιδαζοπυριδινες και μεθοδοι χρησης |
| CY20151100786T CY1116681T1 (el) | 2007-12-19 | 2015-09-11 | 5-ανιλινοϊμιδαζοπυριδινες και μεθοδοι χρησης |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20151100786T CY1116681T1 (el) | 2007-12-19 | 2015-09-11 | 5-ανιλινοϊμιδαζοπυριδινες και μεθοδοι χρησης |
Country Status (28)
| Country | Link |
|---|---|
| US (4) | US7923456B2 (el) |
| EP (2) | EP2222675B1 (el) |
| JP (1) | JP5421925B2 (el) |
| KR (1) | KR101195329B1 (el) |
| CN (1) | CN101945870B (el) |
| AR (1) | AR069803A1 (el) |
| AU (1) | AU2008343065B2 (el) |
| BR (1) | BRPI0819529A2 (el) |
| CA (1) | CA2706571C (el) |
| CL (1) | CL2008003810A1 (el) |
| CY (2) | CY1114663T1 (el) |
| DK (2) | DK2690101T3 (el) |
| ES (2) | ES2546171T3 (el) |
| HK (2) | HK1188209A1 (el) |
| HR (1) | HRP20151002T1 (el) |
| HU (1) | HUE025192T2 (el) |
| IL (1) | IL205977A (el) |
| MX (1) | MX2010006800A (el) |
| MY (1) | MY158829A (el) |
| NZ (1) | NZ586802A (el) |
| PE (2) | PE20131210A1 (el) |
| PL (2) | PL2690101T3 (el) |
| PT (2) | PT2222675E (el) |
| RU (1) | RU2441004C1 (el) |
| SI (2) | SI2222675T1 (el) |
| TW (1) | TWI441820B (el) |
| WO (1) | WO2009085983A1 (el) |
| ZA (1) | ZA201003625B (el) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2188274A4 (en) | 2007-08-03 | 2011-05-25 | Boehringer Ingelheim Int | VIRAL POLYMERASE HEMMER |
| CN101903351B (zh) | 2007-12-19 | 2014-09-10 | 贝林格尔.英格海姆国际有限公司 | 病毒聚合酶抑制剂 |
| WO2011082271A2 (en) | 2009-12-30 | 2011-07-07 | Arqule, Inc. | Substituted triazolo-pyrimidine compounds |
| WO2011082267A2 (en) | 2009-12-30 | 2011-07-07 | Arqule, Inc. | Substituted triazolo-pyrazine compounds |
| CN102020651B (zh) | 2010-11-02 | 2012-07-18 | 北京赛林泰医药技术有限公司 | 6-芳基氨基吡啶酮甲酰胺mek抑制剂 |
| TW201840336A (zh) | 2011-08-01 | 2018-11-16 | 美商建南德克公司 | 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法 |
| WO2013082511A1 (en) | 2011-12-02 | 2013-06-06 | Genentech, Inc. | Methods for overcoming tumor resistance to vegf antagonists |
| MX2014014831A (es) | 2012-06-08 | 2015-02-12 | Hoffmann La Roche | Selectividad de mutante y combinaciones de un compuesto inhibidor de fosfoinositida 3 cinasa y agentes quimioterapeuticos para el tratamiento de cancer. |
| EP2968540A2 (en) | 2013-03-14 | 2016-01-20 | Genentech, Inc. | Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| GB201321729D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| CN106103484B (zh) | 2014-03-14 | 2021-08-20 | 诺华股份有限公司 | 针对lag-3的抗体分子及其用途 |
| AU2015289672A1 (en) | 2014-07-15 | 2017-03-02 | Genentech, Inc. | Compositions for treating cancer using PD-1 axis binding antagonists and MEK inhibitors |
| CN108358939A (zh) * | 2014-07-29 | 2018-08-03 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的杂环化合物及其制备方法和用途 |
| US9993551B2 (en) | 2014-09-13 | 2018-06-12 | Novartis Ag | Combination therapies of EGFR inhibitors |
| KR20170066546A (ko) | 2014-10-03 | 2017-06-14 | 노파르티스 아게 | 조합 요법 |
| AU2015328411C1 (en) | 2014-10-06 | 2022-03-03 | Dana-Farber Cancer Institute, Inc. | Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response |
| CU20170052A7 (es) | 2014-10-14 | 2017-11-07 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo que se unen a pd-l1 |
| EP3233918A1 (en) | 2014-12-19 | 2017-10-25 | Novartis AG | Combination therapies |
| MA41338B1 (fr) * | 2015-01-16 | 2019-07-31 | Hoffmann La Roche | Composés de pyrazine pour le traitement de maladies infectieuses |
| MA41866A (fr) | 2015-03-31 | 2018-02-06 | Massachusetts Gen Hospital | Molécules à auto-assemblage pour l'administration ciblée de médicaments |
| SI3317301T1 (sl) | 2015-07-29 | 2021-10-29 | Novartis Ag | Kombinirane terapije, ki obsegajo molekule protitelesa na LAG-3 |
| EP3316902A1 (en) | 2015-07-29 | 2018-05-09 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
| US20190008859A1 (en) | 2015-08-21 | 2019-01-10 | Acerta Pharma B.V. | Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor |
| BR112018008904A2 (pt) | 2015-11-03 | 2018-11-27 | Janssen Biotech Inc | anticorpos que se ligam especificamente a tim-3 e seus usos |
| CN105399661A (zh) * | 2015-12-14 | 2016-03-16 | 华东师范大学 | 2,6-二溴甲基吡啶的制备方法 |
| CA3007671A1 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
| CN109072311A (zh) | 2016-04-15 | 2018-12-21 | 豪夫迈·罗氏有限公司 | 用于癌症的诊断和治疗方法 |
| WO2017198744A1 (en) | 2016-05-20 | 2017-11-23 | F. Hoffmann-La Roche Ag | Novel pyrazine compounds with oxygen, sulfur and nitrogen linker for the treatment of infectious diseases |
| EP3484885B1 (en) * | 2016-07-14 | 2020-03-04 | H. Hoffnabb-La Roche Ag | Carboxy 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases |
| JP6936848B2 (ja) | 2016-07-14 | 2021-09-22 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 感染症の治療のための新規テトラヒドロピラゾロピリジン化合物 |
| EP3484886B1 (en) | 2016-07-14 | 2020-03-04 | Hoffmann-La Roche AG | 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine and 6,7-dihydro-4h-triazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases |
| WO2018011160A1 (en) * | 2016-07-14 | 2018-01-18 | F. Hoffmann-La Roche Ag | 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases |
| AU2017315572B2 (en) * | 2016-08-23 | 2021-07-15 | Beijing Innocare Pharma Tech Co., Ltd. | Fused heterocyclic derivative, preparation method therefor and medical use thereof |
| CA3073073A1 (en) | 2017-09-08 | 2019-03-14 | F. Hoffmann-La Roche Ag | Diagnostic and therapeutic methods for cancer |
| JP2021503478A (ja) | 2017-11-16 | 2021-02-12 | ノバルティス アーゲー | 組み合わせ治療 |
| WO2019158579A1 (en) | 2018-02-13 | 2019-08-22 | Vib Vzw | Targeting minimal residual disease in cancer with rxr antagonists |
| EP3802609A2 (en) | 2018-05-24 | 2021-04-14 | Janssen Biotech, Inc. | Psma binding agents and uses thereof |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| US11572344B2 (en) * | 2018-11-20 | 2023-02-07 | Nflection Therapeutics, Inc. | Cyanoaryl-aniline compounds for treatment of dermal disorders |
| AU2019402189B2 (en) | 2018-12-20 | 2023-04-13 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| EA202192019A1 (ru) | 2019-02-15 | 2021-11-02 | Новартис Аг | Производные 3-(1-оксо-5-(пиперидин-4-ил)изоиндолин-2-ил)пиперидин-2,6-диона и пути их применения |
| AU2020222346B2 (en) | 2019-02-15 | 2021-12-09 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| CN113747944A (zh) | 2019-04-19 | 2021-12-03 | 詹森生物科技公司 | 用抗psma/cd3抗体治疗前列腺癌的方法 |
| EP3962909B1 (en) * | 2019-04-30 | 2023-10-04 | AiCuris GmbH & Co. KG | Novel oxalyl piperazines active against the hepatitis b virus (hbv) |
| WO2021123996A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
| WO2021260528A1 (en) | 2020-06-23 | 2021-12-30 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| BR112023015097A2 (pt) | 2021-01-28 | 2023-10-03 | Janssen Biotech Inc | Proteínas de ligação a psma e usos das mesmas |
| WO2022169780A1 (en) | 2021-02-02 | 2022-08-11 | Les Laboratoires Servier | Selective bcl-xl protac compounds and methods of use |
| CN117321418A (zh) | 2021-03-18 | 2023-12-29 | 诺华股份有限公司 | 癌症生物标志物及其使用方法 |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| WO2023225320A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
| WO2023225336A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
| WO2024033381A1 (en) | 2022-08-10 | 2024-02-15 | Vib Vzw | Inhibition of tcf4/itf2 in the treatment of cancer |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU11248A1 (ru) | 1927-03-29 | 1929-09-30 | В.С. Григорьев | Способ очистки антрацена |
| ZA711710B (en) * | 1970-05-28 | 1971-12-29 | Squibb & Sons Inc | Amino derivatives of purazolo-pyridine carboxylic acids and esters |
| GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| DE69130683T2 (de) * | 1991-04-22 | 1999-05-06 | Otsuka Pharma Co Ltd | PYRAZOLO[1,5-a]PYRIMIDINDERIVATE UND SIE ENTHALTENDE ANTIINFLAMMATORISCHE MITTEL |
| US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| JPH08175990A (ja) | 1994-12-19 | 1996-07-09 | Mitsubishi Chem Corp | Ｐｉ３キナーゼ阻害剤とその製造法 |
| JPH08176070A (ja) | 1994-12-19 | 1996-07-09 | Mitsubishi Chem Corp | ジデプシド誘導体及びｐｉ３キナーゼ阻害剤 |
| US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| CA2218503C (en) | 1995-04-20 | 2001-07-24 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
| GB9521987D0 (en) | 1995-10-26 | 1996-01-03 | Ludwig Inst Cancer Res | Phosphoinositide 3-kinase modulators |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| ATE225343T1 (de) | 1995-12-20 | 2002-10-15 | Hoffmann La Roche | Matrix-metalloprotease inhibitoren |
| TR199801530T2 (xx) | 1996-02-13 | 1998-11-23 | Zeneca Limited | VEGF �nhibit�rleri olarak kinazolin t�revleri. |
| JP4464466B2 (ja) | 1996-03-05 | 2010-05-19 | アストラゼネカ・ユーケイ・リミテッド | ４―アニリノキナゾリン誘導体 |
| EP0818442A3 (en) | 1996-07-12 | 1998-12-30 | Pfizer Inc. | Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor |
| HUP9903014A3 (en) | 1996-07-18 | 2000-08-28 | Pfizer | Phosphinate derivatives having matrix metalloprotease inhibitor effect and medicaments containing the same |
| US6153609A (en) | 1996-08-23 | 2000-11-28 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| CA2277100C (en) | 1997-01-06 | 2005-11-22 | Pfizer Inc. | Cyclic sulfone derivatives |
| TR199901849T2 (xx) | 1997-02-03 | 2000-02-21 | Pfizer Products Inc. | Arils�lfonilamino hidroksamik asit t�revleri. |
| CA2279863A1 (en) | 1997-02-07 | 1998-08-13 | Pfizer Inc. | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases |
| NZ336836A (en) | 1997-02-11 | 2001-02-23 | Pfizer | Arylsulfonyl hydroxamic acid derivatives suitable for a broad range of medicinal treatments |
| ATE359515T1 (de) | 1997-02-12 | 2007-05-15 | Electrophoretics Ltd | Proteinmarker für lungenkrebs und deren verwendung |
| ATE263147T1 (de) | 1997-08-08 | 2004-04-15 | Pfizer Prod Inc | Derivate von aryloxyarylsulfonylamino hydroxyaminsäuren |
| GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
| GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
| JP4462654B2 (ja) | 1998-03-26 | 2010-05-12 | ソニー株式会社 | 映像素材選択装置及び映像素材選択方法 |
| PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
| PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
| DK1004578T3 (da) | 1998-11-05 | 2004-06-28 | Pfizer Prod Inc | 5-oxo-pyrrolidin-2-carboxylsyrehydroxamidderivater |
| ATE302193T1 (de) | 1999-01-13 | 2005-09-15 | Warner Lambert Co | Benzoheterozyklen und ihre verwendung als mek inhibitoren |
| CZ306810B6 (cs) | 1999-02-10 | 2017-07-19 | Astrazeneca Ab | Použití chinazolinového derivátu jako inhibitoru angiogeneze |
| HUP0202319A3 (en) | 1999-07-16 | 2004-12-28 | Warner Lambert Co | Use of mek inhibitors for the preparation of pharmaceutical compositions treating chronic pain |
| UA72946C2 (uk) | 1999-11-05 | 2005-05-16 | Астразенека Аб | Похідні хіназоліну як інгібітори васкулярного ендотеліального фактора росту (vegf) |
| US6420365B1 (en) * | 2000-01-18 | 2002-07-16 | Neurogen Corporation | Imidazopyridines and related derivatives as selective modulators of bradykinin B2 receptors |
| CA2399358C (en) | 2000-02-15 | 2006-03-21 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
| JP2001247477A (ja) | 2000-03-03 | 2001-09-11 | Teikoku Hormone Mfg Co Ltd | 抗腫瘍剤 |
| US6403588B1 (en) | 2000-04-27 | 2002-06-11 | Yamanouchi Pharmaceutical Co., Ltd. | Imidazopyridine derivatives |
| US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| JP2002020386A (ja) * | 2000-07-07 | 2002-01-23 | Ono Pharmaceut Co Ltd | ピラゾロピリジン誘導体 |
| JP5079202B2 (ja) | 2000-07-18 | 2012-11-21 | 大日本住友製薬株式会社 | セロトニン再取り込み阻害剤 |
| FR2811987A1 (fr) | 2000-07-18 | 2002-01-25 | Expansia Sa | Procede de preparation du 2,2'-dithiobis(ethanesulfonate) de disodium |
| AU2001273498B2 (en) * | 2000-07-19 | 2006-08-24 | Warner-Lambert Company | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| WO2003018057A1 (fr) | 2001-07-26 | 2003-03-06 | Santen Pharmaceutical Co., Ltd. | Remede contre le glaucome contenant en tant qu'ingredient actif un compose presentant un effet inhibiteur de la kinase pi3 |
| US6703414B2 (en) | 2001-09-14 | 2004-03-09 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Device and method for treating restenosis |
| US6894055B2 (en) | 2001-10-24 | 2005-05-17 | Iconix Pharmaceuticals Inc. | Thieno-2′,3′ -5,6pyrimido[3,4-A]-1,2,4-triazole derivatives as modulators of phoshoinositide 3-kinase |
| AU2002349912A1 (en) | 2001-10-24 | 2003-05-06 | Iconix Pharmaceuticals, Inc. | Modulators of phosphoinositide 3-kinase |
| EP1444010A2 (en) | 2001-10-30 | 2004-08-11 | Pharmacia Corporation | Heteroaromatic carboxamide derivatives for the treatment of inflammation |
| AU2003245700A1 (en) | 2002-02-12 | 2003-09-04 | Glaxo Group Limited | Pyrazolopyridine derivatives |
| SG148857A1 (en) | 2002-03-13 | 2009-01-29 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| UA76837C2 (uk) | 2002-03-13 | 2006-09-15 | Еррей Байофарма Інк. | N3 алкіловані похідні бензімідазолу як інгібітори мек |
| CA2489779A1 (en) | 2002-07-10 | 2004-01-22 | Applied Research Systems Ars Holding N.V. | Use of compounds for increasing spermatozoa motility |
| US20040092561A1 (en) | 2002-11-07 | 2004-05-13 | Thomas Ruckle | Azolidinone-vinyl fused -benzene derivatives |
| CN1681811B (zh) | 2002-07-10 | 2010-05-26 | 默克雪兰诺有限公司 | 唑烷酮-乙烯基稠合的-苯衍生物 |
| WO2004017950A2 (en) | 2002-08-22 | 2004-03-04 | Piramed Limited | Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents |
| JP4845379B2 (ja) * | 2002-09-19 | 2011-12-28 | シェーリング コーポレイション | サイクリン依存性キナーゼインヒビターとしてのイミダゾピリジン |
| SE0301373D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
| US20050049276A1 (en) * | 2003-07-23 | 2005-03-03 | Warner-Lambert Company, Llc | Imidazopyridines and triazolopyridines |
| US7144907B2 (en) * | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| AU2004293019B2 (en) * | 2003-11-19 | 2010-10-28 | Array Biopharma Inc. | Bicyclic inhibitors of MEK and methods of use thereof |
| GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
| ATE443063T1 (de) * | 2004-12-01 | 2009-10-15 | Merck Serono Sa | Ä1,2,4ütriazoloä4,3-aüpyridin-derivative zur behandlung hyperproliferativer erkrankungen |
| GB0520657D0 (en) | 2005-10-11 | 2005-11-16 | Ludwig Inst Cancer Res | Pharmaceutical compounds |
| US7888352B2 (en) | 2006-12-07 | 2011-02-15 | Piramed Limited | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
| AU2008343062B2 (en) * | 2007-12-19 | 2013-03-07 | Genentech, Inc. | 8-Anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents |
-
2008
- 2008-12-18 CA CA2706571A patent/CA2706571C/en not_active Expired - Fee Related
- 2008-12-18 DK DK13155995.7T patent/DK2690101T3/en active
- 2008-12-18 SI SI200831088T patent/SI2222675T1/sl unknown
- 2008-12-18 CL CL2008003810A patent/CL2008003810A1/es unknown
- 2008-12-18 DK DK08869100.1T patent/DK2222675T3/da active
- 2008-12-18 JP JP2010539815A patent/JP5421925B2/ja active Active
- 2008-12-18 EP EP08869100.1A patent/EP2222675B1/en active Active
- 2008-12-18 SI SI200831490T patent/SI2690101T1/sl unknown
- 2008-12-18 NZ NZ586802A patent/NZ586802A/en not_active IP Right Cessation
- 2008-12-18 RU RU2010129826/04A patent/RU2441004C1/ru not_active IP Right Cessation
- 2008-12-18 BR BRPI0819529-3A patent/BRPI0819529A2/pt not_active IP Right Cessation
- 2008-12-18 AR ARP080105524A patent/AR069803A1/es unknown
- 2008-12-18 ES ES13155995.7T patent/ES2546171T3/es active Active
- 2008-12-18 TW TW097149416A patent/TWI441820B/zh not_active IP Right Cessation
- 2008-12-18 PE PE2013000381A patent/PE20131210A1/es not_active Application Discontinuation
- 2008-12-18 HU HUE13155995A patent/HUE025192T2/en unknown
- 2008-12-18 CN CN2008801270848A patent/CN101945870B/zh active Active
- 2008-12-18 PT PT88691001T patent/PT2222675E/pt unknown
- 2008-12-18 ES ES08869100.1T patent/ES2437141T3/es active Active
- 2008-12-18 EP EP13155995.7A patent/EP2690101B1/en active Active
- 2008-12-18 WO PCT/US2008/087482 patent/WO2009085983A1/en active Application Filing
- 2008-12-18 PL PL13155995T patent/PL2690101T3/pl unknown
- 2008-12-18 PT PT131559957T patent/PT2690101E/pt unknown
- 2008-12-18 PE PE2008002130A patent/PE20091158A1/es not_active Application Discontinuation
- 2008-12-18 KR KR1020107015884A patent/KR101195329B1/ko not_active IP Right Cessation
- 2008-12-18 AU AU2008343065A patent/AU2008343065B2/en not_active Ceased
- 2008-12-18 MY MYPI2010002814A patent/MY158829A/en unknown
- 2008-12-18 PL PL08869100T patent/PL2222675T3/pl unknown
- 2008-12-18 MX MX2010006800A patent/MX2010006800A/es active IP Right Grant
-
2009
- 2009-04-29 US US12/432,529 patent/US7923456B2/en active Active
-
2010
- 2010-05-21 ZA ZA2010/03625A patent/ZA201003625B/en unknown
- 2010-05-26 IL IL205977A patent/IL205977A/en not_active IP Right Cessation
-
2011
- 2011-02-10 HK HK14101128.7A patent/HK1188209A1/xx unknown
- 2011-02-10 HK HK11101302.8A patent/HK1147254A1/xx unknown
- 2011-03-07 US US13/041,735 patent/US8288408B2/en active Active
-
2012
- 2012-08-15 US US13/586,147 patent/US20120309765A1/en not_active Abandoned
-
2013
- 2013-02-05 US US13/759,850 patent/US9206174B2/en active Active
- 2013-11-21 CY CY20131101033T patent/CY1114663T1/el unknown
-
2015
- 2015-09-11 CY CY20151100786T patent/CY1116681T1/el unknown
- 2015-09-23 HR HRP20151002TT patent/HRP20151002T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1114663T1 (el) | 5-ανιλινοϊμιδαζοπυριδινες και μεθοδοι χρησης | |
| ATE513832T1 (de) | 8-anilinoimidazopyridine und ihre verwendung als antikrebsmittel und/oder entzündungshemmende mittel | |
| WO2010003022A8 (en) | Isoindolone derivatives as mek kinase inhibitors and methods of use | |
| CY1116692T1 (el) | Πυρρολοπυριδινες ως αναστολεις κινασης | |
| ECSP10010510A (es) | Compuestos del inhibidor de raf y métodos de uso de los mismos | |
| WO2008157179A3 (en) | N-substituted azaindoles and methods of use | |
| NO20091197L (no) | Azabenzofuranylforbindelser og anvendelser derav | |
| CR11690A (es) | Pirazolo (3,4-b) piridinas como inhibidores de raf | |
| CY1124148T1 (el) | Θεραπευτικοι παραγοντες για τη θεραπευτικη αγωγη ασθενειων που συνδεονται με ανεπιθυμητο κυτταρικο πολλαπλασιασμο | |
| CY1126122T1 (el) | Αναστολεις πρωτεϊνικης φωσφατασης της τυροσινης | |
| EA201390879A1 (ru) | Трициклические ингибиторы pi3k и способы их применения | |
| CO7081155A2 (es) | Inhibidores de serina/treonina cinasa | |
| EA201490859A1 (ru) | Алкилированные соединения пиперазина в качестве ингибиторов тирозинкиназы брутона | |
| CR20120591A (es) | Derivados de aminopirimidina como moduladores de la lrrk2 | |
| ECSP099786A (es) | Pirazol amidas de ácido carboxílico útiles como microbicidas | |
| CO6511283A2 (es) | Primidinas sustituidas útiles en el tratamiento de enfermedades tales como cancer | |
| GT201200242A (es) | Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6 | |
| MY160349A (en) | Pyridone and aza-pyridone compounds and methods of use | |
| MX2014005282A (es) | Compuestos de 8-fluoroftalazin-1 (2h) -ona. | |
| SG178899A1 (en) | Raf inhibitor compounds and methods of use thereof | |
| MX370906B (es) | Inhibidores de serina/treonina cinasa. | |
| GT201200138A (es) | Derivados de sulfonamida heterocíclicos útiles como inhibidores de mek | |
| MX361157B (es) | Compuestos inhibidores de pi3k de dioxino- y oxazin-[2,3-d]pirimid ina y métodos de uso. | |
| BR112013007041A2 (pt) | animal não humano, descendente, linhagem de células, tecido, explante de órgão, ou cultura dos mesmos, uso do modelo de doenças inflamatórias e métodos para o rastreio de compostos anti-inflamatórios e para a avaliação | |
| CR20110387A (es) | Microbiocidas nuevos |